Daniel Bruetman, M.D., M.M.M.,

(877) 524-4673
Daniel Bruetman, M.D., M.M.M.,
Medical Oncologist
Clinical Expertise
  • Breast Cancer
  • General Medical Oncology
Other Languages Spoken
Spanish
Academic Appointments
  • Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research
Additional Contacts
  • Referring Physicians Phone
    (847) 746-9990
  • Referring Physicians Fax
    (847) 342-4089
  • Referring Physicians Email
    [email protected]

Daniel Bruetman, M.D., M.M.M., joined City of Hope® in February 2023 at the cancer care location in downtown Chicago, Illinois. As a medical oncologist, Dr. Bruetman evaluates and treats patients with a variety of types and stages of cancer, with a special focus on breast cancer.

Dr. Bruetman has over 30 years of oncology experience, as well as leadership expertise from overseeing the development of integrative cancer treatment programs. He also has conducted extensive research on leading-edge innovations in cancer care and worked as a clinical instructor in internal medicine at local hospitals.

Dr. Bruetman earned his medical degree from the University of Buenos Aires School of Medicine in Buenos Aires, Argentina, then completed an internal medicine residency at Advocate Medical Center in Oak Lawn, Illinois, and a medical oncology fellowship at Rush University Medical Center in Chicago, Illinois. Board certified in internal medicine and medical oncology, he received his Master of Medical Management from Carnegie Mellon University in Pittsburgh, Pennsylvania.

Location

Education & Experience

Board Certifications
  • Internal Medicine and Medical Oncology - American Board of Internal Medicine
Degrees
  • University of Buenos Aires School of Medicine, Buenos Aires, Argentina
Residency
  • Internal Medicine - Advocate Christ Medical Center, Oak Lawn, IL
Fellowship
  • Medical Oncology - Rush University Medical Center, Chicago, IL

Publications

  • Phase III Study of Cisplatin, Etoposide, and Concurrent Chest Radiation With or Without Consolidation Docetaxel in Patients With Inoperable Stage III Non–Small-Cell Lung Cancer: The Hoosier Oncology Group and U.S. Oncology Nasser Hanna, Marcus Neubauer, Constantin Yiannoutsos, Ronald McGarry, James Arseneau, Rafat Ansari, Craig Reynolds, Ramaswamy Govindan, Anton Melnyk, William Fisher, Donald Richards, Daniel Bruetman, Thomas 4 Anderson, Naveed Chowhan, Sreenivasa Nattam, Prasad Mantravadi, Cynthia Johnson, Tim Breen, Angela White, Lawrence Einhorn. Dec 2008 Journal of Clinical Oncology
  • Pennington K, Gulec S A, Bruetman D, Hostetter R, Wheeler J, Schwartzentruber D: Phase II trial of multiagent chemotherapy combined with Y-90 microsphere selective internal radiation therapy (chemo-SIRT) in patients with colorectal cancer liver metastases. American Society of Clinical Oncology. Vol 26: Abstract 15011, 2008. 
  • Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01–24/USO- 023—Updated results. L. A. Mina, M. A. Neubauer, R. H. Ansari, R. Govindan, L. H. Einhorn, W. Fisher, D. Bruetman, N. M. Chowhan, C. Johnson, N. H. Hanna. May 2008 Journal of Clinical Oncology 
  • Yttrium-90 microsphere selective internal radiation treatment (SIRT) with concomitant chemotherapy (Chemo-SIRT) as first/second-line therapy in patients with colorectal cancer liver metastases. K. L. Pennington, D. Bruetman, G. Mesoloras, R. Hostetter, S. A. Gulec. Jun 2007 Journal of Clinical Oncology 
  • Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01–24/USO-023. N. H. Hanna, M. Neubauer, R. Ansari, R. Govindan, D. Bruetman, W. Fisher, N. Chowhan, S. Nattam, C. Yiannoutsos, L. Einhorn. Jun 2007 Journal of Clinical Oncology 
  • An analysis of elderly patients (pts) treated on a phase III trial of cisplatin (P) plus etoposide (E) with concurrent radiotherapy (CRT) followed by docetaxel (D) vs observation (O) in pts with stage III non-small cell lung cancer (NSCLC). M. M. Sgroi, M. Neubauer, R. Ansari, R. Govindan, D. Bruetman, W. Fisher, C. Johnson, T. Breen, C. Yiannoutsos, N. Hanna. Jun 2007 Journal of Clinical Oncology
  • Pemetrexed in patients (pts) with relapsed small cell lung cancer (SCLC): A phase II study from the Hoosier Oncology Group N. H. Hanna, R. Ansari, S. Bhatia, R. Govindan, D. Bruetman, M. Hosford, W. Fisher, A. White, T. Breen, B. Juliar. Jun 2006 Journal of Clinical Oncology 
  • Phase III study of cisplatin (P) plus etoposide (E) with concurrent chest radiation (XRT) followed by docetaxel (D) vs. observation in patients (pts) with stage III non-small cell lung cancer (NSCLC): An interim toxicity analysis of consolidation therapy. P. M. Bedano, M. Neubauer, R. Ansari, R. Govindan, L. H. Einhorn, D. Bruetman, A. White, T. Breen, B. Juliar, N. Hanna, Jun 2006 Journal of Clinical Oncology 
  • Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer (NSCLC): A phase II study from the Hoosier Oncology Group A. K. Agarwala, L. Einhorn, W. Fisher, D. Bruetman, J. McClean, D. Taber, M. Titzer, B. Juliar, T. Breen, N. Hanna Jun 2006 Journal of Clinical Oncology 
  • Bruetman, D, Harris, JE, Anderson, K: Differentiation Agents in Malignant Disease. Med Pediatric Oncol 19:71-83, 1991